Auszeichnungen
Referenzen
Unabhängig vom Legal 500-Forschungsteam zusammengestellt.
‘The team has extensive industry experience in providing legal advice for corporate compliance.’
'Mark Zhang and Zhongbin Huang all provide excellent service quality and can understand the needs of enterprises.’
‘The team has extensive experience in transactions, regulation and other areas in the life science and healthcare industries, and can handle some controversial issues such as clinical trial disputes compared to other teams. They have experience in serving first-tier MNCs and domestic biotech firms, and can provide practical guidance relatively quickly.’
‘Mark Zhang has long-term experience in serving MNCs and Chinese biotech clients.’
‘King & Wood Mallesons has extensive experience in the life sciences and healthcare sectors, covering transactions, regulatory compliance, investigations, clinical trials and medical disputes. Their collaboration with major multinational pharmaceutical companies and first-tier biopharmaceutical startups makes them a trusted partner in the industry.’
‘Mark Zhang has extensive expertise in life sciences and healthcare law. He is familiar with transactions, regulatory compliance, investigations, clinical trials, and medical disputes. With his in-depth industry insights and innovative thinking, he provides clients with excellent legal solutions.’
‘Mark Zhang's team has extensive experience in transactions, regulatory compliance and other areas in the life sciences and healthcare industries. The team is able to cope with various daily legal needs of our company.’
‘Solid legal expertise and a thorough understanding of business demands.’
Kernmandanten
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Haier Group Corporation
- Reckitt Benckiser Group plc
- Novo Nordisk A/S
- Teva
- Astellas Pharma Inc./Pfizer
- Novartis AG
- Koninklijke Philips N.V., Philips (China) Investment Co., Ltd.
- China National Medical Device Co., Ltd.
Highlight-Mandate
- Represented Haier Group on its acquisition of 20% shares and 6.58% voting rights in Shanghai RAAS Blood Products Co., Ltd., held by Grifols S.A.
- Represented Novo Nordisk in Semaglutide Compound Patent invalidation, in which SIPO revoked its review decision on invalidating said patent.
- Advised Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. on its USD174m H share IPO, acting as PRC legal advisor to the issuer.
Anwält*innen
Führende Partner*innen
Die stärksten Partner*innen ihres Praxisbereichs, die eine führende Rolle in signifikanten Mandaten einnehmen und weitreichende Anerkennung unter Wettbewerbern und Mandanten genießen.
Mark Zhang
Partner*innen der nächsten Generation
Juniorpartner*innen, die im Markt von Mandanten und Wettbewerbern anerkannt werden und in einigen Mandaten eine Schlüsselrolle einnehmen.
Ting Liu
Yuanyuan Zhu
Praxisleitung
Jianwen Huang
Weitere Kernanwält*innen
Mark Zhang; Jeff Pan; Yuanyuan Zhu; Ting Liu; Zhongbin Huang